Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 41,800 shares, a growth of 86.6% from the March 15th total of 22,400 shares. Currently, 3.3% of the company’s stock are sold short. Based on an average daily trading volume, of 2,210,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Lake Street Capital dropped their target price on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Wednesday, April 2nd.

Evaxion Biotech A/S Stock Down 3.0 %

NASDAQ EVAX traded down $0.04 during mid-day trading on Wednesday, reaching $1.31. The stock had a trading volume of 33,982 shares, compared to its average volume of 596,010. The stock has a market cap of $1.84 million, a PE ratio of -0.90 and a beta of -0.25. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 1 year low of $1.20 and a 1 year high of $22.05. The company has a fifty day moving average price of $1.92 and a 200 day moving average price of $5.91.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Tuesday, April 1st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.19. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.66 million. On average, research analysts expect that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.